Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Anna J Schwecke"'
Autor:
Robert W. Gao, Courtney N. Day, Nathan Y. Yu, Aaron Bush, Adam C. Amundson, Pranitha Prodduturvar, Umair Majeed, Emily Butts, Thomas Oliver, Anna J. Schwecke, Jenesse N. Moffett, David M. Routman, William G. Breen, Ashley L. Potter, Joel Rivera-Concepcion, Bradford S. Hoppe, Steven E. Schild, Terence T. Sio, Yanyan Lou, Vinicius Ernani, Stephen Ko, Kenneth R. Olivier, Kenneth W. Merrell, Yolanda I. Garces, Rami Manochakian, William S. Harmsen, Konstantinos Leventakos, Dawn Owen
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 170
The incidence and predictors of pneumonitis for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) in the era of consolidation durvalumab have yet to be fully elucidated. In this large single institution analysis, we repo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::791ef7c1df955de14a62297bfb9bc62b
https://pubmed.ncbi.nlm.nih.gov/35716632
https://pubmed.ncbi.nlm.nih.gov/35716632
Autor:
Konstantinos Leventakos, Anastasios Dimou, Nathan R. Foster, Lynn M. Flickinger, Sri Harsha Tella, Julian R. Molina, Aaron Scott Mansfield, Randolph Marks, Anna J Schwecke, Craig Hocum, Jenesse Nicole Moffett, Ashley Potter, Alex A. Adjei
Publikováno v:
Journal of Clinical Oncology. 40:TPS8604-TPS8604
TPS8604 Background: Chemoimmunotherapy followed by durvalumab maintenance yields a median overall survival of 12.9 months in patients with extensive stage Small Cell Lung Cancer (ES SCLC), which is an improvement over chemotherapy alone. However, 90%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebdac8aa280518c00b2ebe619b849f00
https://doi.org/10.1200/jco.2022.40.16_suppl.tps8604
https://doi.org/10.1200/jco.2022.40.16_suppl.tps8604